drugset / Trial / NCT04768699
Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
RandomizedCrossoverOpen-labelTreatment
Summary
Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQG203 | Protein / enzyme biologic | 30 ug/kg | Intravenous |
| Subject | TQG203 | Protein / enzyme biologic | 90 ug/kg | Intravenous |
| Subject | TQG203 | Protein / enzyme biologic | 180 ug/kg | Intravenous |
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | 90 ug/kg | Intravenous |